The report, titled “Erectile Dysfunction Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”, from Transparency Market Research offers valuable insights into the market. According to the report, the global erectile dysfunction drugs market will decline at a 4.50% CAGR during the forecast period from 2013 to 2019. In 2012, the global erectile dysfunction drugs market was estimated at US$4.3 bn and by 2019, the market is projected to shrink to a value of US$3.4 bn.
Browse the full Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 report at http://www.transparencymarketresearch.com/erectile-dysfunction-drugs.html
The global erectile dysfunction drugs market will decline in the coming few years due to the growing threat of counterfeit drugs. Expiration of patents of many blockbuster drugs will further impede the growth of the global ED drugs market. The global erectile dysfunction drugs market will also be suppressed by the narrowing of insurance coverage for erectile dysfunction treatment. The rising prevalence of sexually transmitted diseases among ED drug users will further challenge the market. On the other hand, factors such as the rising geriatric population and growing awareness and patient education will fuel the global erectile dysfunction drugs market.
By brand, the global erectile dysfunction drugs market is segmented into Cialis (tadalafil), Viagra (sildenafil citrate), Stendra/Spedra (avanafil), Levitra/Staxyn (vardenafil), Zydena (udenafil), Mvix (mirodenafil), MUSE (medicated urethral system for erection), and Helleva (lodenafil carbonate). The Viagra segment held the largest share in the global erectile dysfunction drugs market; this segment held a 45% share in the global erectile dysfunction drugs market. Nevertheless, the patent expiration of Viagra, particularly outside U.S. in 2013, has led to a substantial decline in the sales of this drug.
In the U.S., Viagra will continue to hold a major revenue share in the global erectile dysfunction drugs market due to the patent exclusivity extension till 2020. Cialis (tadalafil) will also experience shrinking market revenue. In 2012, the Cialis segment was worth US$1.9 bn and held the second largest share in the market. This segment will observe a decline at a 12.6% CAGR during the forecasting horizon.
Among pipeline drugs, the global erectile dysfunction drugs market is divided into Uprima (apomorphine), Vitaros (alprostadil), and others (melanocortin activators, topiglan, and gene therapy). Region-wise, the global erectile dysfunction drugs market is classified into Europe, North America, Asia Pacific, and Rest of the World (RoW). North America dominates the global erectile dysfunction drugs market and will continue its dominance in terms of revenue during the forecast period. This region is the most lucrative market for ED drugs due to the presence of blockbuster drugs such as Cialis and Viagra in the U.S. market. On the other hand, the rising market consolidation and introduction of cheaper products will result in rapid adoption of these drugs in the emerging markets.
Players in the global erectile dysfunction drugs market will benefit from the opportunity provided by generics and novel molecule combinations. Novel drug delivery methods are projected to emerge as a good growth opportunity for companies in this market. Some of the key players operating in the global erectile dysfunction drugs market are Vivus, Pfizer, Eli Lilly and Company, Bayer, and Apricus Biosciences.
Key Segments of the Erectile Dysfunction Drugs Market
Global Erectile Dysfunction Drugs Market, by Brand
- Viagra (Sildenafil Citrate)
- Cialis (Tadalafil)
- Levitra/Staxyn (Vardenafil)
- Stendra/Spedra (Avanafil)
- Zydena (Udenafil)
- MUSE (Medicated Urethral System for Erection)
- Mvix (Mirodenafil)
- Helleva (Lodenafil Carbonate)
Global Erectile Dysfunction Drugs Market, by Pipeline
- Vitaros (Alprostadil)
- Uprima (Apomorphine)
- Others (Topiglan, Melanocortin Activators, Gene Therapy)
Global Erectile Dysfunction Drugs Market, by Geography
- North America
- Asia Pacific
- Rest of the World (RoW)
Browse : Our new press releases http://www.transparencymarketresearch.com/pressrelease/erectile-dysfunction-drugs-market.htm
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453